Eton Pharmaceuticals, Inc. ETON
62.12 USD +0.13 (+0.21%)
As ofNov 19, 2026, 12:14 PM EST
61.26 Day range 63.38
14.27 52-week range 70.64
- YTD
- +267.36%
- 1 year
- +269.32%
News
seekingalpha.com Eton Pharmaceuticals: The Commercial Model Is Finally Scaling Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a…benzinga.com B. Riley Securities Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $81 B. Riley Securities analyst Madison El-Saadi maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $70 to $81.
benzinga.com Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $68 to $80.
benzinga.com HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $70 to $80.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 19.5% to $0.36 during Friday's pre-market session. The company's market cap stands at $27.1 million. Eton Pharmaceuticals (NASDAQ:ETON)…
benzinga.com Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Cloudflare jumped 14.6% after beating Q3 estimates; JFrog and Eton gained, while Site Centers and Biostem plunged premarket.
benzinga.com Eton Pharmaceuticals Q3 2026 Earnings Call Transcript Eton Pharmaceuticals (NASDAQ:ETON) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…benzinga.com Eton Pharmaceuticals Announces Its ET-700 Zing Acetate Formulation Shows Lower Rate Of Drug Related Adverse Events In Pilot Trial Than GALZIN; No Serious Adverse Events Seen Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced
benzinga.com Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027 ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like…
